Artal Group S.A. lowered its holdings in Axovant Sciences Ltd (NYSE:AXON) by 30.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 175,000 shares of the biotechnology company’s stock after selling 75,000 shares during the quarter. Artal Group S.A. owned 0.16% of Axovant Sciences worth $4,058,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after buying an additional 355 shares during the last quarter. American International Group Inc. grew its stake in Axovant Sciences by 7.1% during the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares during the last quarter. Legal & General Group Plc grew its stake in Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after buying an additional 1,168 shares during the last quarter. Teachers Advisors LLC grew its stake in Axovant Sciences by 5.2% during the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock worth $513,000 after buying an additional 2,038 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/artal-group-s-a-has-4-06-million-position-in-axovant-sciences-ltd-axon/1573556.html.

Axovant Sciences Ltd (NYSE AXON) traded up 0.940% during mid-day trading on Tuesday, hitting $23.095. 479,001 shares of the stock traded hands. The stock’s market capitalization is $2.48 billion. The company has a 50 day moving average price of $20.84 and a 200-day moving average price of $19.73. Axovant Sciences Ltd has a one year low of $11.01 and a one year high of $24.46.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.12). Equities analysts anticipate that Axovant Sciences Ltd will post ($2.36) earnings per share for the current fiscal year.

Several analysts have weighed in on AXON shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $31.00 price objective on shares of Axovant Sciences in a research note on Friday, June 9th. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price objective (up from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. upped their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. CIBC upped their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. Finally, BidaskClub raised shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Four equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $26.05.

Axovant Sciences Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd (NYSE:AXON).

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.